Advanced Enzyme Q1 FY27 Earnings Call — Analysis (NSE: ADVENZYMES)

Soft Q1 with 2% YoY revenue growth and margin compression, but management reaffirms double-digit FY27 growth and announces ₹69.7 Cr buyback.

· Analysis by Alpha Inflection

Result quality: stable — Steady quarter. Management sentiment: neutral.

The take

Q1FY27 Revenue ₹189.8 Cr ( +2% YoY ) .

Results

Revenue ₹189.8 Cr (+2% YoY), EBITDA margin 27% (-300bps YoY), PAT ₹38.6 Cr (-5% YoY); an incremental sales reversal of ₹10 Cr impacted the quarter.

Financial highlights

Advanced Enzyme Q1 FY27 reported figures
MetricValueChangeBasis
Revenue₹189.8 Cr+2%yoy · Q1FY27 · vs Q1FY26
Revenue₹189.8 Cr-7%qoq · Q1FY27 · vs Q4FY26
EBITDA₹51.0 Cr-10%yoy · Q1FY27 · vs Q1FY26
EBITDA₹51.0 Cr-19%qoq · Q1FY27 · vs Q4FY26
EBITDA Margin27%-300bpsyoy · Q1FY27 · vs Q1FY26
PAT₹38.6 CrQ1FY27

Guidance

FY27 double-digit revenue growth and consolidated EBITDA margin recovery to ~30%.

Key themes

Muted Q1, buyback, and recovery confidence.

View source

Research and educational content only. Not investment advice.